GeneDx Holdings Corp. Class A WGS

Key Takeaways:Record Testing Volume: GeneDx delivered over 30,000 exome and genome tests in Q2, up 32% year-over-year, and returned to profitability a quarter ahead of schedule. Price Projection: Based on current assumptions, WGS stock could reach $137 by December 2028.

GAITHERSBURG, Md., September 09, 2026--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

GAITHERSBURG, Md., September 01, 2026--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity

GAITHERSBURG, Md., August 24, 2026--GeneDx and Seattle Children’s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.

GAITHERSBURG, Md., August 11, 2026--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.

In early August 2026, GeneDx Holdings Corp. reported second-quarter revenue of US$114.44 million with a net loss of US$17.74 million, reaffirmed its full-year 2026 revenue outlook, and announced a private placement of 81,967 Class A shares at US$61.00 each with participation from a Blackstone affiliate. The combination of higher revenue alongside a shift from profit to loss, together with fresh equity capital from a major institutional investor, gives investors new information on GeneDx’s...

GAITHERSBURG, Md., August 06, 2026--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.

Moby summary of GeneDx Holdings Corp.'s Q2 2026 earnings call

GeneDx returns to profitability ahead of schedule, driven by 32% exome and genome volume growth and expanded commercial coverage.

GAITHERSBURG, Md., August 03, 2026--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]

Polen Capital, an investment management company, released its second-quarter 2026 investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here. Polen 5Perspectives Small Growth Composite Portfolio returned 33.22% gross and 32.83% net of fees, respectively, in the second quarter of 2026, compared to the 25.71% return of the […]

GAITHERSBURG, Md., July 16, 2026--GeneDx (Nasdaq: WGS) announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026.